Improved Drug Susceptibility Testing (DST) for Mycobacteria
Funds faster drug-susceptibility tests for tuberculosis and related mycobacterial infections that skip slow culture-based methods.
The standard way to find out which drugs a tuberculosis strain will respond to is a culture-based test, and culture is slow — slow enough that a patient can be on the wrong drug for weeks before anyone finds out. This notice funds replacing that wait.
The targets are drug susceptibility tests for mycobacterial drugs generally: drugs already used against tuberculosis and against clinically importa…
Development of rapid genotypic and improved phenotypic drug susceptibility tests, not requiring full culture growth, for mycobacterial drugs including current tuberculosis and non-tuberculous mycobacterial disease treatments, new drugs, and drugs in late-stage clinical development.
Sign up free to see the funding breakdown
Sign up free to see the industries in scope
Sign up free to see the full eligibility
Sign up free to see how to apply
Sign up free to see what you submit
Sign up free to see how they score you
Sign up free to see the timeline
Sign up free to see where teams trip up